Connect Biopharma Holdings Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNTB research report →
Range $4 – $8
Price Chart
About the company
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody.
- CEO
- Barry D. Quart
- IPO
- 2021
- Employees
- 64
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on CNTB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $38.05M
- P/E
- -1.19
- PEG
- 0.19
- P/S
- 14.64
- P/B
- 3.28
- EV/EBITDA
- -0.73
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1225.29%
- Net Margin
- -1207.88%
- ROE
- -171.83%
- ROIC
- -268.03%
Latest fiscal year · YoY change
- Revenue
- $64.00K-99.8%
- Gross Profit
- $64.00K-99.8%
- Op Income
- $-58,074,000
- Net Income
- $-55,480,000-255.0%
- EPS
- $-1.00-257.1%
- OCF Growth
- -116.9%
- FCF Growth
- -112.0%
- 52W High
- $3.82
- 52W Low
- $0.55
- 50D MA
- $0.91
- 200D MA
- $2.06
- Beta
- -0.22
- RSI (14)
- 31
- Avg Volume
- 3.98M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Connect Biopharma said its lead AD program is on track for an October China readout, with global Phase 3 set to start before year-end and cash expected to fund operations into at least 2024.· September 13, 2022
- CBP-201 AD: China pivotal Stage 1 data from the first 255 patients is due in October, potentially about eight months earlier than originally planned if positive.
- The company plans to start its first global CBP-201 Phase 3 study before the end of 2022 and is designing a broader 4-trial registrational program.
- CBP-201 asthma enrollment is now expected to finish in the first half of 2023, six months later than previously anticipated, with data in the second half of 2023.
- CBP-307 in ulcerative colitis showed a statistically significant clinical remission rate at a higher dose and is being positioned as a partnering opportunity.
- Cash, cash equivalents, short-term and long-term investments were $212.9 million at June 30, 2022, which management said should fund operations into at least 2024.
For the six months ended June 30, 2022, cash, cash equivalents, short-term and long-term investments were $212.9 million (RMB1,429.1 million), versus RMB1,706.9 million at December 31, 2021. R&D expense was $50.8 million (RMB340.8 million), up from RMB217.8 million, and administrative expense was $10.7 million (RMB71.8 million), up from RMB48.0 million. Net loss was $59.8 million (RMB401.3 million) versus a net loss of RMB942.5 million in the prior-year period, with the year-over-year improvement mainly reflecting prior fair value adjustments on preferred stock. Looking ahead, management said CBP-201 China Stage 1 topline data should be reported in October, the global Phase 3 AD study should start before year-end 2022, asthma enrollment should complete in the first half of 2023, and asthma topline data should follow in the second half of 2023. They also said CBP-201 China data could support an NDA filing in 2024 and potential approval as early as 2025 if results are positive.
Dr. Zheng Wei emphasized CBP-201 as the company’s main value driver, saying the China CDE interaction could accelerate the BLA timeline and that the October readout may become a key catalyst for partnering discussions. He framed the AD market as crowded but argued that IL-4R-alpha biology remains compelling and that CBP-201 could differentiate via efficacy and longer maintenance dosing every four weeks. On CBP-307, he said the Phase 2 package supports a partnering story because the drug appears to hit its target and achieved statistically significant clinical remission at a higher dose.
Steven Chan focused on liquidity and expense trends, noting $212.9 million in cash and investments at June 30, 2022, which he said should fund operations into at least 2024 based on the current plan. He attributed the higher R&D spend to clinical trial costs for CBP-201 in AD and asthma, CBP-307 in UC, plus additional R&D headcount, while admin costs rose due to personnel, stock-based compensation, professional services, and public-company infrastructure. He also explained that the prior-year net loss was inflated by RMB674.3 million of fair value adjustments on preferred stock that was converted in last year’s IPO.
Analysts asked how CBP-201 can stand out in the crowded AD field, whether CBP-307 could be partnered this year, and what the asthma opportunity looks like. Management said the AD strategy is to compete on efficacy plus convenient maintenance dosing, and that there has been continued partner interest in CBP-307, though no timing was given. On China regulation, management said the CDE’s feedback and the ability to hold a pre-BLA meeting after the 16-week data are positive signs, but approval will depend on the pivotal China data; on the October topline, they said they expect to disclose the primary week-16 endpoint, key secondary endpoints such as IGA and itch, and safety in more detail than the prior Phase 2b release.
The positive case is that CBP-201 appears to have meaningful momentum: China pivotal data is coming soon, the global Phase 3 plan is already designed, and management believes the program could support earlier-than-expected regulatory steps if the data are positive. The company also has enough cash to operate into at least 2024, reducing near-term financing pressure.
The main risks are execution and timing: asthma enrollment slipped by six months, the company still has no partnered deal for CBP-307, and approval in China depends on whether the pivotal AD data are positive. Management also acknowledged the AD market is crowded, and the next CBP-174 study is still undefined, including formulation considerations and the possibility that the program may need a different approach.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 27.1%
- Shares Outstanding
- 64.49M
- Float Shares
- 17.51M
of shares held by institutions
58 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ikarian Capital, LLC | 4.54M | ▼ 849.95K |
| Bml Capital Management, LLC | 3.86M | ▲ 3.29M |
| 683 Capital Management, LLC | 1.28M | ▲ 385.00K |
| Blackrock, Inc. | 1.02M | ▲ 149.48K |
| Boothbay Fund Management, LLC | 973.73K | ▼ 260.85K |
| Richmond Brothers, Inc. | 833.33K | ▲ 297.72K |
| Perceptive Advisors LLC | 792.70K | 0 |
| Adar1 Capital Management, LLC | 700.00K | ▼ 42.40K |
| Quinn Opportunity Partners LLC | 505.00K | ▲ 505.00K |
| Knott David M Jr | 419.87K | ▼ 25.00K |
| Marshall Wace, Llp | 376.03K | ▲ 40.39K |
| Geode Capital Management, LLC | 240.17K | ▼ 17.28K |
Held by 53 ETFs
Biggest fund positions in CNTB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Xanthopoulos Kleanthis Gabriel | other | 5,000 |
| Sep 30, 26 | LIU JEAN I | other | 8,984 |
| Jun 30, 26 | Xanthopoulos Kleanthis Gabriel | other | 3,738 |
| Jun 30, 26 | LIU JEAN I | other | 6,718 |
| May 29, 26 | Huang James | buy | 150,000 |
| Mar 31, 26 | Xanthopoulos Kleanthis Gabriel | other | 2,816 |
| Mar 31, 26 | LIU JEAN I | other | 5,061 |
| Mar 31, 26 | Huang James | buy | 1,160,000 |
| Mar 18, 26 | Huang James | other | 0 |
| Mar 16, 26 | Szekeres David Leslie | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNTB coverage
Recent articles, reports, and earnings notes.
No research on CNTB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNTB report →Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 16
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
seekingalpha.com · Oct 23
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
zacks.com · Oct 22
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
zacks.com · Oct 19
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical Contrast
defenseworld.net · Oct 5
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
marketbeat.com · Oct 4
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
benzinga.com · Sep 30
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
seekingalpha.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.